Reviews/Perioperative Immunotherapy Solid Tumours/Adjuvant nivolumab benefit independent of PD-L1 status
Bladder · PERIO-BLAD-03 · v2
A large randomised trial found that patients who received nivolumab after surgery for muscle-invasive urothelial cancer stayed free of disease longer than those given placebo [13]. The effect looked bigger in patients whose tumours carried the PD-L1 marker than in the whole trial population [13][10]. But the corpus never reports a separate result for patients whose tumours lacked the marker, so the claim that these PD-L1-negative patients also benefited is worked out indirectly rather than measured. Everything here comes from one trial reported twice, with no second drug or second study to confirm the pattern. The panel treated the overall benefit as solid but the PD-L1-negative half of the claim as not actually shown.
In CheckMate 274, adjuvant nivolumab improved disease-free survival over placebo in the whole trial population and in the PD-L1 >=1% subgroup, with a larger point estimate in the latter (DFS hazard ratio 0.70 overall versus 0.55 for PD-L1 >=1%) [13]. The MIBC analysis of the same trial reports a DFS hazard ratio of 0.63 across all MIBC patients and an overall-survival hazard ratio of 0.70 overall versus 0.48 in the PD-L1 >=1% subgroup [10]. Both reports describe only the intention-to-treat and PD-L1 >=1% subgroups; neither states a PD-L1 <1% hazard ratio [13][10]. The other adjuvant or perioperative trials in the corpus test different drugs: pembrolizumab [11], atezolizumab [12], and durvalumab [15]. The contested point: The division is whether a benefit specifically in PD-L1-negative patients can be stated. No PD-L1 <1% estimate is reported in [13] or [10], so that half of the claim is inferred from the mixed intention-to-treat result rather than observed, and the larger PD-L1-positive magnitude rests on a descriptive subgroup-versus-ITT comparison with no interaction test reported.
All 29 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Perioperative Immunotherapy Solid Tumours, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The claim asserts benefit 'observed in PD-L1-negative patients', but neither [13] nor [10] reports any PD-L1 <1% subgroup hazard ratio. Only ITT and PD-L1 >=1% are reported; the PD-L1-negative benefit is an inference from the mixed ITT population, not an observation in this corpus.
The evidence base is a single trial: [10] and [13] are both CheckMate 274 (NCT02632409). There is no independent replication of adjuvant nivolumab's PD-L1 subgroup behaviour in the corpus; the other adjuvant trials ([11] pembrolizumab, [12] atezolizumab, [15] durvalumab) are different drugs.
Where it remains uncertain. No PD-L1 <1% subgroup estimate is reported in [13] or [10], and no interaction test supports the magnitude ordering, so the PD-L1-negative benefit is inferred rather than observed.
Aleatory
OS in [10] is from preplanned interim analyses with medians not reached and prespecified significance boundaries not crossed, so the PD-L1 >=1% OS HR 0.48 carries substantial sampling uncertainty.
Epistemic
The benefit rests on one trial reported twice ([13], [10]); no second nivolumab study in the corpus confirms the PD-L1 subgroup pattern.
Inferential
The claim reads a PD-L1-negative benefit out of the mixed intention-to-treat result [13], which includes PD-L1-positive patients and cannot isolate the negative subgroup.
The load-bearing papers from a corpus of 29, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Confirms overall benefit and a larger OS effect in PD-L1 >=1% tumours; still provides no PD-L1 <1% subgroup estimate.
“With 3-y median follow-up, consistent benefit in DFS was observed with NIVO vs PBO in all MIBC pts and across prior NAC subgroups.”
Panel auditInternal validity: high · scope of inference: Adjuvant nivolumab in high-risk MIBC, DFS and interim OS, PD-L1 >=1% versus overall.Key limitations: PD-L1-negative subgroup not reported · OS interim, boundary not crossed · MIBC/subgroup analyses exploratory · conference abstract
Establishes adjuvant nivolumab DFS benefit in the overall (ITT) MIUC population, which includes PD-L1-negative patients.
“Among patients with a PD-L1 expression level of 1% or more, the percentage of patients was 74.5% and 55.7%, respectively (hazard ratio, 0.55; 98.72% CI, 0.35 to 0.85; P<0.001).”
Panel auditInternal validity: high · scope of inference: Adjuvant nivolumab in high-risk MIUC after radical surgery, DFS in ITT and PD-L1 >=1%.Key limitations: PD-L1-negative subgroup not reported separately · PD-L1 cutoff is >=1% not high/low · DFS not OS endpoint reported
2 of 29 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
The overall benefit and larger PD-L1-positive effect are well-supported, but the compound claim overreaches on an unobserved PD-L1-negative subgroup and rests on a single trial, warranting an Uncertain tier.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Reported PD-L1 <1% subgroup estimate. The PD-L1-negative half of the claim cannot be assessed because no hazard ratio for this group is reported in [13] or [10]. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: Publish the prespecified PD-L1 <1% DFS and OS hazard ratios from CheckMate 274 alongside the existing ITT and PD-L1 >=1% estimates.
Open question: Do PD-L1-negative (PD-L1 <1%) patients derive a disease-free or overall-survival benefit from adjuvant nivolumab? Why it is still open: Neither [13] nor [10] reports any PD-L1 <1% hazard ratio; the benefit in this group is inferred from the pooled ITT result.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19